Related by context. All words. (Click for frequent words.) 67 multicenter randomized controlled 66 adenoma recurrence 64 Cholesterol Levels SPARCL 63 Prostate Cancer Prevention 63 Prostate Lung Colorectal 63 Aggressive Reduction 62 colorectal adenoma 62 Randomized controlled 62 Carotid Revascularization Endarterectomy vs. 61 STRIDE PD 61 CALERIE 61 androgen suppression 61 Myocardial Infarction Study 61 SIMPADICO 61 prospective observational studies 61 NSABP B 60 mg BID dose 60 Tiotropium 60 somatostatin analog 60 Randomized Evaluation 60 Prolongs Survival 60 fosbretabulin 60 AA Amyloidosis 60 prospectively stratified 60 prospective randomized multicenter 60 FOLPI 60 BCIRG 60 CLARITY TIMI 60 Raloxifene STAR 60 EURIDIS 60 Meta analyzes 60 advanced adenoma 60 Aromatase Inhibitors 60 relapsed MM 60 double blinded randomized 60 Primary endpoints 60 Multicenter Automatic Defibrillator Implantation 60 Hepatotoxicity 60 HCV SPRINT 60 unfractionated heparin UFH 59 CARE HF 59 Glucosamine Chondroitin Arthritis 59 COSTAR II 59 substudy 59 Randomized Phase II 59 oral rivaroxaban 59 placebo controlled Phase III 59 Placebo Controlled Trial 59 ONTARGET 59 placebo controlled clinical 59 Aortic Stenosis 59 Prospective Randomized 59 MEND CABG 59 Ischemic 59 Multiple Ascending Dose 59 AIR CF1 59 desvenlafaxine succinate 59 Cardiotoxicity 59 GISSI 59 β blockers 59 CHAMPION PCI 59 TAXUS ATLAS 59 Restenosis 59 CAMMS# 59 selenium supplementation 59 multicenter randomized 59 viral kinetic 59 dosing cohorts 59 AVOREN 59 Stent Restenosis 59 trials RCTs 59 HCV RESPOND 2 59 Phase III AFFIRM 58 Intervention Trial 58 plasma homocysteine 58 Ovarian Cancer Screening 58 postintervention 58 Randomized Study 58 EVEREST II 58 Randomised 58 Oral Fingolimod 58 Secondary efficacy endpoints 58 Thrombolysis 58 GOUT 58 secondary efficacy endpoint 58 MGd 58 Controlled Trial 58 ARCOXIA 58 TMC# C# 58 B vitamin supplementation 58 thromboembolic 58 Liraglutide Effect 58 Levels Linked 58 Gastric Cancer 58 insulin detemir 58 Reduce Cardiovascular 58 ACCORD Lipid 58 prospectively defined 58 dosing cohort 58 Teriflunomide 58 Breast Density 58 UACR 58 NATRECOR R 58 RE LY ® 58 Thorough QT 58 Diabetic Macular Edema 58 DAPT 58 Endometrial Cancer 58 flutamide 58 conjugated equine estrogen 58 subanalysis 58 Platelet Inhibition 58 Desvenlafaxine Succinate 58 Adenomas 58 interferon gamma 1b 58 Randomized Double blind 58 BARI 2D 58 Adenoma Prevention 58 multicenter Phase II 58 secondary efficacy endpoints 58 multicenter phase 58 multicenter placebo controlled 58 Multicenter Randomized 58 CHARM Added 58 double blinded placebo 58 Pooled Analysis 58 BENICAR HCT 58 colorectal adenomas 58 MERLIN TIMI 58 phase IIIb 58 Subgroup analysis 58 XIENCE V demonstrated 58 NEUVENGE 57 WHEL 57 Spine Patient Outcomes 57 longitudinal observational study 57 Comorbidities 57 multicenter randomized placebo controlled 57 multicenter randomized clinical 57 WHIMS 57 aspirin clopidogrel 57 CATIE AD 57 RECORD1 57 thorough QT 57 HF ACTION 57 Val HeFT 57 serum phosphate 57 BEXXAR Therapeutic Regimen 57 Stent Thrombosis 57 RE LY 57 mg/m2 cohort 57 mammographic density 57 phase Ib 57 Edge STudy 57 Cardiovascular Events 57 elevated ALT 57 Hormone Refractory Prostate Cancer 57 thromboembolic complications 57 APTIVUS 57 ug dose 57 Protease Inhibitors 57 DCCT 57 ECASS 57 APTIVUS r 57 prospective multicentre 57 doxorubicin docetaxel 57 Randomized Clinical Trials 57 SORT OUT III 57 Cholinesterase Inhibitors 57 Thromboembolism 57 glucose insulin 57 oral prednisolone 57 NCCTG N# 57 azilsartan medoxomil 57 Intervention Effectiveness 57 Multicenter 57 lipid lowering agents 57 multicentre randomized 57 Non Responders 57 Acute Ischemic Stroke 57 number NCT# ClinicalTrials.gov 57 Hematologic 57 Randomized Phase 57 riociguat 57 exploratory endpoints 57 randomized blinded 57 Placebo controlled 57 Zemplar Capsules 57 multicenter randomized double 57 Cervical Dysplasia 57 prospective randomized placebo 57 Randomized Controlled 57 Raloxifene Evaluation MORE 57 ATACAND 57 aplindore 57 myopathy rhabdomyolysis 57 Demonstrates Sustained 57 HYVET 57 serum triglycerides 57 TDF FTC 57 multicenter multinational 57 Coronary Artery Calcium 57 fasting plasma 57 beta carotene supplementation 57 Unstable Angina 57 VADT 57 Nonalcoholic Fatty Liver Disease 57 AIM HIGH 57 CYT# potent vascular disrupting 57 Tumor Response 57 evaluating tivozanib 57 Infarct 57 CALGB 57 Adjuvant Breast Cancer 57 Complications Trial 57 postoperative AF 57 GSK# [001] 57 Ranolazine 57 CYP#D# inhibitor 57 controlled multicenter Phase 57 Uterine Cancer 57 EINSTEIN DVT 57 Hsp# Inhibitor 57 NCT# ClinicalTrials.gov 57 Relapsing Multiple Sclerosis 57 Phase Ib II 57 randomized multicenter 57 cilostazol 57 Memory Study WHIMS 57 prospective observational cohort 57 antiepileptics 57 ascending dose 57 nonrandomized 57 ASTEROID 56 morphometric vertebral fractures 56 ADMIRE HF 56 pramlintide metreleptin combination 56 PHPT 56 IMPACT DCM 56 mITT population 56 CIMZIA TM certolizumab pegol 56 DLTs 56 Ovarian PLCO Cancer 56 LEXIVA r 56 Randomized Trials 56 zonisamide SR 56 ACCOMPLISH 56 Microalbuminuria 56 simvastatin ezetimibe 56 endometrial hyperplasia 56 ibandronate 56 Tigecycline 56 landmark ATHENA 56 oral FTY# 56 epoetin alpha 56 dose escalation phase 56 colesevelam HCl 56 Dialysis Outcomes 56 RIO Lipids 56 serum leptin 56 Digital Mammographic Imaging 56 iPrEx 56 REALITY Trial 56 Newly Diagnosed Multiple Myeloma 56 Fondaparinux 56 Motesanib 56 Pharmacodynamic 56 Main Outcome Measure 56 Atherosclerosis MESA 56 Initiated Phase 56 DES implantation 56 Prostate AdenoCarcinoma Treatment 56 prospective nonrandomized 56 ancrod 56 Clinical Antipsychotic Trials 56 Lipid Lowering Treatment 56 Endocrine Therapy 56 ENGAGE AF TIMI 56 Vildagliptin 56 evaluable subjects 56 symptomatic VTE 56 prospective multicenter study 56 Contraindications 56 doxorubicin cyclophosphamide 56 Phase IIIb clinical 56 Major Adverse Cardiac 56 MADIT II 56 GISSI HF 56 ENDEAVOR IV 56 Phase III ThermoDox 56 Phase Ib clinical 56 SABCS 56 Pramlintide 56 specified secondary endpoints 56 URTI 56 prospective observational 56 HIV HCV coinfected 56 Multicenter Phase 56 lanthanum carbonate 56 BR.# 56 NTx 56 iPrEx study 56 retrospective cohort 56 Hypotension 56 CURRENT OASIS 7 56 randomized crossover 56 Coronary Artery Bypass Graft 56 See CLINICAL PHARMACOLOGY 56 evaluating mipomersen 56 CIN2 + 56 randomized #:#:# 56 BZA CE 56 ENDEAVOR III 56 Oral Insulin Capsule 56 Multiethnic Study 56 Colorectal Cancers 56 Depressive Symptoms 56 Eluting Stent 56 ACRIN 56 atazanavir ritonavir 56 Phase III multicenter 56 randomizing patients 56 Subgroup analyzes 56 ERATO 56 Valsartan 56 Ramipril 56 elotuzumab 56 intermittent dosing 56 NO# [002] 56 MAGE A3 ASCI 56 Randomized Double Blind 56 CALGB # [001] 56 Phase 1a clinical 56 comparator arm 56 CALGB # [002] 56 vitamin B# folic acid 56 blinded randomized placebo controlled 56 SPIRIT FIRST 56 ACUITY trial 56 Interferon Beta 56 fluvastatin 56 Antihypertensive 56 CLARITY study 56 UKPDS 56 MEND CABG II 56 Antitumor 56 placebo controlled clinical trials 56 Carotid Stenting 56 HDAC Inhibitor 56 HPTN 56 ritonavir boosted lopinavir 56 Non Alcoholic Steatohepatitis 56 ExTRACT TIMI 56 neoadjuvant 56 blinded placebo controlled 56 Postmenopausal 56 Pioglitazone 56 Lp PLA 2 56 HeFH 56 Fracture Risk 56 placebo controlled trials 56 tolvaptan 56 multicentre randomized controlled 56 Wisconsin Sleep Cohort 56 deferiprone 56 multicentre 56 dose cohort 56 TOHP 56 Shows Efficacy 56 Subtypes 56 INSPIRE Trial Phase III 55 EMPHASIS HF 55 brivaracetam 55 serum urate levels 55 Patients Treated With 55 Screening Trial DMIST 55 National Emphysema Treatment 55 preclinical pharmacokinetic 55 Multidrug 55 specified primary endpoint 55 carotid atherosclerosis 55 recurrent venous thromboembolism 55 mg/m2 dose 55 AVERROES 55 Kaplan Meier analysis 55 mcg BID 55 lispro 55 Clinical Outcome 55 HORIZONS AMI 55 cisplatin gemcitabine 55 placebo controlled studies 55 Lymphocytic 55 Catheter Ablation 55 phase IIa 55 CAPRIE 55 lymphadenectomy 55 Phase III Pivotal 55 Xelox 55 Nonalcoholic Steatohepatitis 55 Carotid Endarterectomy 55 Pivotal Clinical Trial 55 hypercholesterolaemia 55 dose atorvastatin 55 Phase III Clinical Trial 55 Bone Mineral Density 55 Meta Analysis 55 Erythropoietic therapies may 55 Unfractionated Heparin 55 nab paclitaxel 55 colorectal liver metastases 55 pravastatin Pravachol 55 HGPIN 55 prespecified secondary 55 CYPHER R Sirolimus eluting 55 Phase 1b trial 55 Clinical Trial Data 55 PEG IFN 55 Screening Trial 55 corticosteroid dose 55 myocardial uptake 55 Localized Prostate Cancer 55 Hematological 55 multicentre randomized double 55 urinary N telopeptide 55 Multicentre 55 Alpha Tocopherol Beta Carotene 55 TEAEs 55 subgroup analyzes 55 mg administered orally 55 hyperhomocysteinemia 55 recurrent metastatic 55 EQUIP OB 55 randomized controlled multicenter 55 prospective multicenter 55 chromium supplementation 55 Events MACE 55 Phase IIIb 55 masked placebo controlled 55 AVN# Phase 55 TIMI Study Group 55 Ozarelix 55 ACTIVE W 55 teriflunomide 55 Stenting Trial CREST 55 carotid artery stenting CAS 55 dose titration 55 Atherosclerotic 55 advanced adenomas 55 Combination REOLYSIN R 55 Trandolapril 55 Immunotherapeutic 55 Castration Resistant Prostate Cancer 55 paclitaxel eluting stents 55 Phase IIb III 55 Pivotal Trial 55 paclitaxel poliglumex 55 Cognitive Problems 55 prucalopride 55 R# #mg BID 55 controlled multicenter 55 pharmacokinetic PK study 55 Improves Survival 55 Celecoxib APC trial 55 Histopathological 55 COPERNICUS 55 CIMZIA ™ 55 PROSTVAC VF 55 obese postmenopausal 55 urolithiasis 55 multicentre prospective 55 Intervention Effectiveness CATIE 55 ARIXTRA 55 concomitant medications 55 APEX PD 55 atherogenic dyslipidemia 55 Prospective Randomized Trial 55 Randomized Controlled Trials 55 Pharmacokinetic 55 randomized Phase IIb 55 meta regression 55 BPS IC 55 specific antigen PSA 55 sipuleucel T 55 placebo controlled multicenter 55 posaconazole 55 Refractory Angina 55 BRIM3 55 atorvastatin #mg 55 irbesartan 55 Investigational Treatment 55 Phase III randomized 55 fallopian tube cancers 55 Antiviral Activity 55 platelet dysfunction 55 Randomized Phase III 55 clevidipine 55 psoriatic arthritis PsA 55 demonstrated antitumor activity 55 Risk Stratification 55 IFN α 55 NICE SUGAR 55 FDG PET imaging 55 papillary renal cell carcinoma 55 corrected QT interval 55 fasting serum 55 MEVACOR 55 Adverse Event 55 estramustine 55 Cognitive Function 55 TRITON TIMI 55 Phase 2b Clinical Trial 55 Intervention Trial GAIT 55 ToGA 55 RE MODEL 55 leiomyomas 55 Deforolimus 55 Phase IIA 55 Study AREDS 55 placebo controlled randomized 55 rosuvastatin #mg 55 bazedoxifene conjugated estrogens 55 TAXOTERE R 55 composite endpoint 55 TAXUS IV 55 randomized Phase 2b 55 Folfox 55 PROactive study 55 nasopharyngitis headache 55 recurrent glioblastoma multiforme 55 FDG-PET/CT 55 Patients Receiving 55 Long Lesion 55 canakinumab 55 Common Toxicity Criteria 55 Meets Primary Endpoint 55 Sorafenib HCC Assessment 55 Double Blind Randomized 55 clinical pharmacology studies 55 #mg/day [001] 55 pivotal bioequivalence 55 prospective cohort 55 IIIa inhibitor 55 Multi Ethnic Study 55 Randomized Clinical Trial 55 Lung Cancer Trial 55 Phase III Psoriasis 55 Monotherapy 55 Chronic Liver Disease 55 Randomized Controlled Trial 55 Predict Response 55 pharmacokinetic parameters 55 CRLX# 55 QTc prolongation 55 NSABP 55 atrasentan 55 Impaired Glucose Tolerance 55 NHANES III 55 Randomized trials 55 Pharmacologic 55 Demonstrates Efficacy 55 concurrent chemoradiation 55 mg RDEA# 55 XIENCE V PROMUS Stent 55 APPRAISE 55 genotypic resistance 55 OPT CHF 55 FAME Study 55 ARCALYST ® rilonacept 55 NSTE ACS 55 Suicidality 55 preoperative radiotherapy 55 MIST II 55 Androxal TM 55 Trial Evaluating 55 nondiabetic patients 55 Dietary Modification Trial 55 Drospirenone 55 Cardiovascular Risk 55 overt nephropathy 55 PLCO 55 venous thromboembolic disease 55 CARDIA study 55 MIRAPEX ER 55 AST ALT 55 longitudinal cohort study 55 coronary stenosis 55 AZT zidovudine Retrovir 55 Inflammatory Markers 55 finasteride Proscar 55 Tolvaptan 55 biliary tract cancer 55 Long Term Efficacy 54 Hemodialysis Patients 54 macrovascular events 54 Serious Adverse Events 54 undergone radical prostatectomy 54 plasma lipid 54 cinacalcet 54 ATAC Arimidex Tamoxifen Alone 54 placebo controlled Phase 54 metformin sulfonylurea 54 RCTs 54 Lipid Lowering 54 EXPLORE Xa 54 Apolipoprotein B 54 umol L 54 abacavir lamivudine 54 atherosclerotic renal artery stenosis 54 NSABP C 54 AEGR 54 designated HVTN 54 Dose Response 54 plasma pharmacokinetics 54 baseline FEV 54 EXJADE 54 Virologic 54 evaluating satraplatin 54 nonfatal MI 54 coadministration 54 Health Initiative Observational 54 bepotastine besilate nasal spray 54 Lowers Risk 54 Warfarin Coumadin 54 6R BH4 54 dose Iluvien 54 vulvovaginal atrophy 54 Ischemic Stroke 54 BOLDER II 54 Excretion 54 ALN HPN 54 atherothrombotic disease 54 FOLFOX6 chemotherapy regimen 54 Parathyroid Hormone 54 cardiovascular calcification 54 Genetic Markers 54 RE LY trial 54 blind placebo 54 PEGylated interferon beta 1a 54 maximally tolerated dose 54 Neuroprotective Effects 54 HOPE TOO 54 Completes Patient Enrollment 54 QTc intervals 54 MIRAPEX 54 stone formers 54 Adjuvant Chemotherapy 54 RRMS patients 54 trastuzumab emtansine T DM1 54 visceral metastases 54 Brief Psychiatric 54 Phase 2a Trial 54 heFH 54 dalteparin 54 Renal Function 54 RSD# oral 54 Urocortin 2 54 chills fever headache 54 multicenter prospective 54 dietary questionnaires 54 serum estradiol 54 metabolic parameters 54 folate supplementation 54 beclomethasone dipropionate 54 Fulvestrant 54 Peripheral Arterial 54 Patency 54 randomized controlled clinical trials 54 Acute MI 54 NEVO RES 54 recurrent DVT 54 metabolite concentrations 54 Phase IIB 54 Thromboembolic 54 Docosahexaenoic Acid 54 Hepatitis C Antiviral 54 albiglutide 54 Vertebral Fractures 54 prospectively randomized 54 EEG abnormalities 54 pharmacodynamic parameters 54 esophageal carcinoma 54 extrapyramidal symptoms 54 blinded randomized 54 CIMZIA TM 54 Pivotal Phase 54 Hepatocellular Carcinoma HCC 54 Diabetes ACCORD 54 impaired insulin secretion 54 PFO migraine 54 budesonide foam 54 INTEGRILIN R 54 periprocedural MI 54 GAMMAGARD 54 PreCISe 54 Mycophenolate Mofetil 54 haematologic 54 Antiepileptic Drug 54 hypercholesterolemic patients 54 serum phosphorous 54 HoFH 54 randomized multicentre 54 Metastatic Prostate Cancer 54 F FDG PET 54 EchoCRT 54 Shows Promise Against 54 INCB# [003] 54 Fracture Intervention Trial 54 PIX# [002] 54 Glatiramer Acetate 54 Achieves Primary Endpoint 54 Oxidized LDL 54 histologically confirmed 54 Proellex TM 54 serum lipid 54 Angiographic 54 TG MV 54 INFERGEN 54 salmeterol fluticasone propionate 54 acute coronary syndromes ACS 54 Predict Risk 54 pravastatin therapy 54 prognostic variables 54 carotid endarterectomy CEA 54 Invasive Breast Cancer 54 prospective multicenter randomized 54 ThermoDox ® clinical 54 Prevent Stroke 54 vitamin D calcium 54 Dose escalation 54 LAB CGRP 54 TOLAMBA 54 PREZISTA r arm 54 Phase III Clinical Trials 54 Phase #b/#a clinical 54 vitreous floaters 54 randomized clinical 54 melphalan prednisone 54 Pivotal Phase III 54 endocrine responsive 54 Pharmacokinetic PK 54 alpha 2a 54 lipid lowering therapy 54 RIO Diabetes 54 PSN# [002] 54 neratinib 54 Advanced Renal Cell 54 bivariate analyzes 54 unresectable HCC 54 paricalcitol 54 randomized multicenter Phase III 54 Acute Coronary Syndromes 54 urinary calcium 54 Tarceva TM 54 aldosterone antagonists 54 Combination Treatment 54 tacrolimus ointment 54 Pre RELAX AHF 54 COPD exacerbation 54 undetectable HBV DNA 54 efavirenz EFV 54 Ophena 54 definite stent thrombosis 54 Systolic Blood Pressure 54 nonmetastatic 54 ST Segment Elevation 54 phase IIb trial 54 ABCSG 54 AIR2 Trial 54 pharmacologically active isomer 54 PROactive 54 Pegylated Liposomal Doxorubicin 54 Postmenopausal Women 54 Cognitive Impairment 54 Reduces Mortality 54 ARBITER 6 54 Diabetes Interventions 54 weekly subcutaneous injections 54 Malignant Glioma 54 glatiramer acetate 54 macrovascular disease 54 PARTNER Trial 54 Cytogenetic 54 pimecrolimus cream 54 Rosuvastatin 54 BRIM2 54 tenofovir emtricitabine 54 gallium nitrate 54 AIR CF2 54 VESTASYNC 54 PRoFESS 54 lexidronam injection 54 T1c 54 TAXUS VI 54 AGILECT R 54 MERIT ES 54 apnea hypopnea 54 serum lipids 54 ritonavir boosted 54 QTc 54 Neovascular AMD 54 Clinical Efficacy 54 pharmacokinetic PK 54 coronary revascularization 54 AREDS 54 EQUATE OB 54 Antiplatelet Therapy 54 prostate cancer CaP 54 PEGINTRON TM 54 dose escalation Phase 54 serum IGF 54 Lenocta 54 Phase Ib Clinical Trial 54 Akt inhibitor 54 mg TID 54 phase IIb clinical 54 Eye Disease 54 echocardiographic parameters 54 primary hypercholesterolemia 54 intima media thickness 54 Prospective Multicenter 54 TIMP 1 54 standard chemotherapy regimen 54 ximelagatran 54 Hypertrophy 54 spirometric 54 Abciximab 54 daily subcutaneous injections 54 multicenter clinical 54 timepoints 54 nausea somnolence 54 p = #.# [003] 54 MVax R 54 tapentadol ER 54 telaprevir dosing 54 AGILECT ® 54 angiographic outcomes 54 metastatic castration resistant 54 TLUS 54 fluvastatin Lescol 54 Left Ventricular Dysfunction 54 Improves Outcomes 54 Fixed Dose 54 PROTECT AF 54 Hypercholesterolemia 54 Subgroup Analysis 54 Arrhythmias 54 Glufosfamide 54 Relieve Depression 54 moderate hepatic impairment 54 HMG CoA reductase inhibitors 54 Phase 2a Study 54 cardiovascular morbidity 53 4mg/kg 53 prespecified 53 ISTODAX 53 VIVUS Announces 53 Tanespimycin 53 Prostate Cancer Outcomes 53 Toxicities 53 Dyslipidemia 53 Relapsing Remitting Multiple Sclerosis 53 pramlintide 53 intravenous dosing 53 achieved statistical significance 53 polyp recurrence 53 Left Ventricular Hypertrophy 53 Severe Sepsis 53 ezetimibe simvastatin 53 ALLHAT 53 R lenalidomide 53 trodusquemine 53 beta blocker therapy 53 duplex ultrasonography 53 Anthracycline 53 underwent surgical resection 53 randomized 53 Candesartan 53 CIMZIA R 53 multicenter trials 53 triglyceride concentrations 53 postoperative mortality 53 Vascugel ® 53 nulliparous women 53 dose proportionality 53 multivitamin supplementation 53 RG# ITMN 53 Secondary endpoints 53 Phase 2b Trial 53 aspartate aminotransferase AST 53 overnight polysomnography 53 Sibutramine Cardiovascular Outcomes 53 Bioequivalence 53 velafermin 53 brachial artery flow 53 Efficacy endpoints 53 Group RTOG 53 virological response 53 Venous Thromboembolism 53 inflammatory biomarkers 53 Diabetic Nephropathy 53 Therapeutic Arthritis 53 antidiabetic medication 53 ongoing Phase 1b 53 Study Evaluating 53 EDEMA3 trial 53 confirmatory Phase III 53 Hepatocellular Carcinoma 53 Hyperlipidemia 53 Generalized Anxiety Disorder 53 hypercalciuria 53 ORAL Sync 53 normotensive 53 REYATAZ ritonavir 53 Mortality Risk 53 PLMs 53 SUTENT ® 53 observational studies 53 oxycodone CR 53 tHcy 53 #F FDG PET CT 53 evaluating Actimmune 53 Cystectomy 53 subcutaneous dose 53 aripiprazole Abilify 53 CUSTOM III 53 SYMMETRY trial 53 Celebrex celecoxib 53 timepoint 53 Therapeutic Efficacy 53 ENESTnd 53 ZYBRESTAT fosbretabulin 53 intensive lipid lowering 53 antiplatelet drugs 53 KIF6 carriers 53 olmesartan 53 TAXUS V 53 nadroparin 53 preoperative chemotherapy 53 ORENCIA ® 53 ARB telmisartan 53 receptor tyrosine kinase inhibitor 53 relapsing remitting MS RRMS 53 Colorectal Adenomas 53 fludarabine cyclophosphamide 53 Recurrent Breast Cancer 53 pharmacokinetic PK profile 53 p# biomarker 53 Chronic Heart Failure 53 macrovascular 53 DSMB recommended 53 CVD mortality 53 Homeostasis 53 Vidaza ® 53 ACTOS ® 53 tarenflurbil 53 IIa clinical 53 Framingham Offspring 53 CRESTOR #mg 53 JAK Inhibitor 53 Polymorphism 53 MARINOL R 53 cerebrovascular events 53 DAS# CRP 53 serum homocysteine 53 male Wistar rats 53 transcranial Doppler ultrasound 53 Pharmacokinetic parameters 53 microgram kg 53 eculizumab therapy 53 Non inferiority 53 PROTECT II 53 Stop Hypertension DASH 53 HDL Selective Delipidation 53 Severe Asthma 53 PRESEPT 53 phase IIb III 53 Pafuramidine 53 venlafaxine ER 53 GH deficiency 53 mg q8h 53 placebo controlled 53 rimonabant #mg 53 headache nasopharyngitis 53 pharmacodynamic effects 53 postoperative chemotherapy 53 periprocedural 53 Septic Shock 53 Paroxysmal Nocturnal Hemoglobinuria PNH 53 IFN alfa 53 antidiabetic medications 53 modified REGENESIS Phase IIb 53 dose regimens 53 REMINYL ® 53 intima media thickness IMT 53 Decitabine 53 GnRH agonists 53 BENICAR 53 endometrial carcinoma 53 PreCISe study